<DOC>
	<DOCNO>NCT00940498</DOCNO>
	<brief_summary>This two-part study compound call PF-05212384 ( also know PKI-587 ) . The purpose part 1 identify Maximum Tolerated Dose ( MTD ) PF-05212384 use Continual Reassessment Method ( CRM ) . Part 1 include subject solid tumor . In Part 2 two cohort enrol . One cohort ass safety , tolerability preliminary efficacy 20 subject MTD include subject breast cancer , ovarian cancer , endometrial cancer , colorectal cancer renal cancer glioblastoma ( type brain tumor ) . The cohort include 5 15 subject type tumor consent provide tumor biopsy participate study .</brief_summary>
	<brief_title>Study PF-05212384 ( Also Known PKI-587 ) Administered Intravenously To Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Pathologic diagnosis solid tumor Incurable cancer , disease progression follow least 1 therapy standard treatment available opinion investigator . At least 1 evaluable lesion per RECIST criterion Clinically unstable primary metastatic CNS tumor Subjects know diabetes QTc interval great 470 m .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Dose Finding</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Tumors</keyword>
	<keyword>PF-05212384</keyword>
</DOC>